Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163475
Status:
COMPLETED
Last Update Posted:
2016-10-25
First Post:
2005-09-12
Brief Title:
Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma 12 to 70 y BY217M2-015
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
The MOVE-study Morning Versus Evening Administration of 500 mcg Roflumilast Once Daily for 6 Weeks in Patients With Asthma
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Bronchial asthma is among the worlds most prevalent diseases Roflumilast is a novel orally active selective enzyme inhibitor phosphodiesterase 4 inhibitor which has shown effectiveness in the treatment of asthma
The aim of the study is to compare the effect of roflumilast on lung function symptoms and use of rescue medication in patients with stable asthma Roflumilast will be administered orally either in the morning or in the evening at one dose level The study duration consists of a baseline period 1 to 2 weeks and a treatment period 6 weeks The study will provide further data on safety tolerability and effectiveness of roflumilast
The aim of the study is to compare the effect of roflumilast on lung function symptoms and use of rescue medication in patients with stable asthma Roflumilast will be administered orally either in the morning or in the evening at one dose level The study duration consists of a baseline period 1 to 2 weeks and a treatment period 6 weeks The study will provide further data on safety tolerability and effectiveness of roflumilast
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None